Shots:

• Insitro to receive $15M upfront- $35M near term operational milestone- $200M as preclinical- development- regulatory and commercial milestones on each 5 targets & royalties on sales. Insitro has also an option to co-develop & co-detail in the US with profit share in China and will receive milestones and royalties on sales (Ex-US)
• Gilead will utilize Insitro‘s technology to discover & develop therapies for NASH and can advance upto five from identified targets. Additionally- in Apr’19- Gilead also collaborated with Novo Nordisk for developing potential therapies for NASH
• The Insitro Human (ISH) platform is utilized to discover & develop therapies applying machine learning- human genetics and functional genomics- providing understanding of disease progression- suggest candidate targets- and predict their responses 

Ref: Gilead | Image:Gilead